- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00809835
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We are proposing a randomized double blind clinical trial of galantamine and our innovative computer-assisted version of CBT, alone and in combination, to improve treatment outcome and cognitive functioning among cocaine users. The proposed study will be the first to evaluate a cognitive enhancing medication as a means of enhancing the effects of an extremely promising empirically validated behavioral therapy for addiction, and hence bridge cognitive neuroscience and behavioral therapies development.
The aim is to conduct a 12 week randomized placebo controlled trial, using a 2x2 factorial model, that will evaluate the efficacy of adding computer assisted training in CBT ("CBT4CBT") and galantamine to standard treatment for 160 cocaine abusing or dependent methadone-maintained individuals. Participants will be randomized to (1) standard treatment (TAU) plus placebo, (2) TAU plus galantamine, (3) TAU plus CBT4CBT plus placebo, or (4) TAU plus CBT4CBT plus galantamine.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06604
- Kinsella Treatment Center (KTC)
-
Stratford, Connecticut, United States, 06615
- Regional Network of Programs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females between ages of 18 and 50
- Enrolled in RNP methadone program and stable on methadone for at least 3 weeks
- Current cocaine abuse or dependence according to DSM-IV criteria
- No current medical problems and normal ECG
- If female, not currently pregnant or breast feeding and using reliable birth control
- Fluent in English and have at least a 6th grade reading level
- Can commit to 12 weeks of treatment and are willing to be randomized
Exclusion Criteria:
- Current major psychiatric illness including mood, psychotic or anxiety disorder
- History of major medical illnesses including asthma, chronic obstructive lung disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances
- Use of medications including beta blockers and NASAIDs
- Known allergy to Galantamine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard Treatment As Usual (TAU)
Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals.
This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment.
The counseling program's theoretical orientation is described as client-centered.
|
|
Experimental: TAU Plus Galantamine
Standard treatment plus Galantamine.
In this study, we will use 8 mg galantamine extended release (ER).
Galantamine ER is used once daily.
The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
|
Daily 8 mg galantamine capsule
Other Names:
|
Experimental: TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)
TAU plus computer assisted CBT plus placebo.
All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project.
Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
|
CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures.
The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
|
Experimental: TAU plus CBT plus galantamine
Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
|
Daily 8 mg galantamine capsule
Other Names:
CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures.
The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cocaine Use
Time Frame: 12 weeks
|
Reduction in cocaine use, operationalized as the frequency of cocaine use by month using timeline followback.
|
12 weeks
|
Cocaine Abstinence
Time Frame: 12 weeks
|
operationalized by percentage of drug-free urine specimens submitted (We will use the Branan ToxCup Drug Screen Cup onsite TESTCUP system for detection of cocaine, methamphetamine, THC, benzodiazepine, and opioids) at 12 Weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive Function
Time Frame: 12 weeks
|
A composite using a carefully selected neuropsychological battery that includes measures of executive cognitive functioning frequently affected among cocaine users, likely to be important moderators of CBT4CBT, and sensitive to galantamine effects. These will include measures of multiple aspects of attention, cognitive inhibition, sustained attention (CANTAB), decision making (BART), and memory (digit span). Scores ranged from -1.77 to 1.42 with a higher score indicating higher cognitive functioning. |
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathleen M Carroll, Ph.D., Yale University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- 0708002943
- R01DA015969-13 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine Dependence
-
W. Michael HootenNational Institute on Drug Abuse (NIDA)Recruiting
-
University of ArkansasNational Institute on Drug Abuse (NIDA); Baylor College of MedicineCompleted
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)Completed
-
Tong LeeNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedCocaine Dependence | Methamphetamine DependenceUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence | Cocaine Dependence | Methamphetamine DependenceUnited States
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)RecruitingAlcohol Dependence | Substance Abuse | Cocaine Dependence | Opiate Dependence | Cocaine AbuseUnited States
-
Johns Hopkins UniversityCompletedBehavior, Addictive | Heroin Dependence | Opioid Dependence | Cocaine Dependence | Cocaine AbuseUnited States
-
Wayne State UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Heroin Dependence | Cocaine Abuse or DependenceUnited States
-
University of PennsylvaniaCompletedCocaine DependenceUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine Use Disorder | Cocaine Use Disorder | Cocaine Dependence | Methamphetamine Dependence | Stimulant Use Disorder | Methamphetamine Abuse | Cocaine Abuse | Stimulant Abuse | Stimulant UseUnited States
Clinical Trials on Galantamine
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Samsung Medical CenterJanssen Korea, Ltd., KoreaCompleted
-
Ludwig-Maximilians - University of MunichUnknownAlzheimer's DiseaseGermany
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompletedBipolar DisorderUnited States
-
The University of Texas Health Science Center,...Completed
-
Janssen Pharmaceutical K.K.CompletedAlzheimer's DiseaseJapan
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAlzheimer Disease
-
Actavis Inc.Completed
-
Actavis Inc.Completed